CYTOKINE PHARMASCIENCES, INC. Patent applications |
Patent application number | Title | Published |
20120046325 | Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis). | 02-23-2012 |
20110245156 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Compounds are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed. | 10-06-2011 |
20110237679 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Compounds, salts thereof, and tautomers thereof are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed. | 09-29-2011 |
20110224301 | HMGB1 EXPRESSION AND PROTECTIVE ROLE OF SEMAPIMOD IN NEC - Methods are described, which include the administration of semapimod or guanylhydrazone containing compounds, salt thereof, or a combination of the compound and a salt thereof for the inhibition, treatment, and/or prevention of any of NEC, a condition associated with the release of HMGB1, a condition associated with the release of iNOS protein, a condition associated with the release of Bax protein, a condition associated with the release of Bad protein, a condition associated with the release of COX-2 protein, or a condition associated with the release of RAGE, or a combination thereof to a subject in need thereof. | 09-15-2011 |
20110144189 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING - The present invention relates to compounds having the formula: | 06-16-2011 |
20110020321 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR - Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | 01-27-2011 |
20100184091 | Method for determining MIF content - The present invention relates to diagnostic methods for determining migration inhibitory factor (MIF) mRNA content in a sample, wherein MIF is human MIF polypeptide having a molecular weight of approximately 12.5 kDa and kits for detecting MIF. | 07-22-2010 |
20100179225 | POI Prevention - A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof. | 07-15-2010 |
20100137566 | Compounds and Methods Used to Treat Infectious Diseases - The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught. | 06-03-2010 |
20100016391 | Isoxazoline Compounds Having MIF Antagonist Activity - Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis). | 01-21-2010 |
20090036540 | Guanylhydrazones in Methods of Treatment or Diagnosis as Modulators of Signal Transduction - A method is provided for the treatment of a condition mediated by raf kinase, which includes administering a guanylhydrazone to a subject in need thereof. A method is also provided, which includes modulating or inhibiting signal transduction in a c-raf pathway with at least one guanylhydrazone. Another method is provided, which includes contacting one or more human mononuclear cells with at least one guanylhydrazone and at least one lipopolysaccharide to obtain one or more treated cells; contacting at least one selected from the group including said treated cells, one or more lysates thereof, and combinations thereof, with at least one surface-bound peptide in a surface-bound peptide array; and selectively modulating or inhibiting the phosphorylation of the surface-bound peptide. | 02-05-2009 |
20080262090 | Guanylhydrazone Salts, Compositions, Processes of Making, and Methods of Using - The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use. | 10-23-2008 |
20080260723 | Method of Treatment and Bioassay Involving Macrophage Migration Inhibitory Factor (MIF) as Cardiac-Derived Myocardial Depressant Factor - One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor. | 10-23-2008 |